A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

To attend the event or participate virtually, please register here. The event will provide an update on Oculis’ portfolio of three innovative late-stage clinical candidates, offer further details on ...

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

Oculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edema: Zug, Switzerland Monday, April 14, 2025, 15:00 Hrs [IST] Oculis Ho ...

The American Academy of Sleep Medicine has released a new position statement emphasizing the clinical significance of sleepiness and its impact on performance, health, mood, safety, and quality of ...

There remains a significant need ... innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05 ...